Business Description
Newron Pharmaceuticals SpA
NAICS : 325412
ISIN : IT0004147952
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -1.24 | |||||
Debt-to-Equity | -1.58 | |||||
Debt-to-EBITDA | -3.45 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.8 | |||||
Beneish M-Score | -3.63 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.6 | |||||
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 23.71 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 89.53 | |||||
9-Day RSI | 78.42 | |||||
14-Day RSI | 68.7 | |||||
6-1 Month Momentum % | 20.06 | |||||
12-1 Month Momentum % | 61.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 2.27 | |||||
Days Sales Outstanding | 106.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -5.31 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -215.4 | |||||
Net Margin % | -270.28 | |||||
FCF Margin % | -192.57 | |||||
ROA % | -68.04 | |||||
ROIC % | -71.97 | |||||
ROC (Joel Greenblatt) % | -720.7 | |||||
ROCE % | -136.6 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 136.14 | |||||
PS Ratio | 24.6 | |||||
EV-to-EBIT | -15.01 | |||||
EV-to-Forward-EBIT | 73.35 | |||||
EV-to-EBITDA | -15.21 | |||||
EV-to-Forward-EBITDA | 73.35 | |||||
EV-to-Revenue | 31.2 | |||||
EV-to-Forward-Revenue | 17.37 | |||||
EV-to-FCF | -16.2 | |||||
Price-to-Median-PS-Value | 0.83 | |||||
Earnings Yield (Greenblatt) % | -6.66 | |||||
FCF Yield % | -7.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Newron Pharmaceuticals SpA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 6.638 | ||
EPS (TTM) (CHF) | -0.981 | ||
Beta | 1.64 | ||
Volatility % | 80.89 | ||
14-Day RSI | 68.7 | ||
14-Day ATR (CHF) | 0.12694 | ||
20-Day SMA (CHF) | 7.603123 | ||
12-1 Month Momentum % | 61.42 | ||
52-Week Range (CHF) | 4.18322 - 10.39992 | ||
Shares Outstanding (Mil) | 19.23 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Newron Pharmaceuticals SpA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Newron Pharmaceuticals SpA Stock Events
Event | Date | Price(CHF) | ||
---|---|---|---|---|
No Event Data |
Newron Pharmaceuticals SpA Frequently Asked Questions
What is Newron Pharmaceuticals SpA(LTS:0QOI)'s stock price today?
When is next earnings date of Newron Pharmaceuticals SpA(LTS:0QOI)?
Does Newron Pharmaceuticals SpA(LTS:0QOI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |